MAC Attorney Tells Physician to Stop Disclosing Lab Payment Data

Health Care Compliance Association (HCCA)
Contact

Health Care Compliance Association (HCCA)

Report on Medicare Compliance 29, no. 35 (October 5, 2020)

A California physician on Sept. 18 received a letter from a Medicare administrative contractor (MAC) that ordered him to stop sharing pricing information about labs, which he said he does to draw attention to overpayments.

The cease-and-desist letter from a law firm representing Palmetto GBA told Bruce Quinn, M.D., a former MAC medical director, that the data, which he often obtains through the Freedom of Information Act (FOIA), is “restricted by intellectual property laws.” The law firm instructed him to delete it and turn over the names of people who downloaded it.

“I don’t think Medicare contractors should send cease-and-desist letters about public documents,” Quinn said. He called it an “inversion” of the normal program integrity and FOIA process. “Palmetto regards CMS FOIA information about overpayments as de facto ‘business secrets’ that I must destroy,” Quinn wrote in an email to CMS officials, including the director of the Medicare Contractor Management Group.

In a return email, a CMS official said, “We are looking into several different issues your experience with Palmetto has raised, including the cease and desist letter you received on behalf of Palmetto’s counsel unbeknownst to CMS. Please give us a few days to sort this out. We will be in touch.”

Quinn said he regularly identifies underpayments by his laboratory clients and overpayments to their competitors and reports them to MACs. “My clients are playing by the rules and are annoyed competitors are getting paid twice as much,” he said. Quinn also has a website and blogs about payment disparities. One example is a common genetic test for breast cancer risk called BRCA testing. The normal coding is CPT 81162, with a current Medicare fee schedule price of $1,825. However, the Palmetto instruction is for selected labs to bill BRCA testing with a nonspecific unpriced code, 81479, for which the instructions assign a much higher price of $2,395, he said.

One way Quinn gets the information is the FOIA process, which he said he has been using for four years without incident. Then out of the blue, he received the cease-and-desist letter from the law firm Barnwell Whaley Patterson & Helms LLC.

The letter addressed Quinn’s possession and sharing of a Master Edit File from MolDX, which Palmetto developed under contract with CMS, he said. MolDX, which is used in 28 states, determines coverage and reimbursement for molecular diagnostic testing, and produces local coverage determinations and edits. The letter said MolDX is the intellectual property of Palmetto and that “possession, use, copying and publication of the File is restricted by intellectual property laws.” In addition to wanting assurance from Quinn that the file “was deleted in all electronic forms,” the law firm said “we also request that you provide to us names and contact information for all persons and entities known to you that downloaded the Master Edit File” or transmitted all or part of it.

Because of the cease-and-desist letter, Quinn took down the link to the MolDX data from his website, but he didn’t destroy it and hopes CMS will step in. He didn’t provide the names of people who downloaded it.

[View source.]

Written by:

Health Care Compliance Association (HCCA)
Contact
more
less

Health Care Compliance Association (HCCA) on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.